Closed dental company working to transfer patients
Citing cash-flow problems, Allcare Dental and Dentures shut down operations in 14 states, including Indiana, last week.
Health Care Businesses
Articles
Lilly’s Solpura may lack data to prove effectiveness
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
Lilly bumped up federal lobbying in third quarter
The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
Lilly, other big drugmakers shut out by FDA in 2010
Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world’s largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Lilly suspends late-stage trial for melanoma drug
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
Nursing home firm to pay $376K in Medicaid case
Indiana Attorney General Greg Zoeller says a nursing home company will pay $376,000 to the state and federal governments over accusations that it submitted ineligible bills to Medicaid.
St. Francis plans $20M medical campus near Greenwood
The project along Indiana 37 will include outpatient facilities and an emergency room.
St. Francis-WellPoint deal is a sign of the times
St. Francis, which operates three Indianapolis-area hospitals, and WellPoint, the giant health insurer, announced this month that they have agreed to jointly form an accountable care organization.
Lilly, Acrux receive FDA approval for Axiron
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
Medical device maker expanding in Fort Wayne
L.H. Medical Corp. said it plans to create up to 65 jobs by 2013 and invest $5.4 million to more than triple the size of its manufacturing operations.
Drugmakers seek Republican allies to defeat cost-cutting panel
Pharmaceutical firms led by Eli Lilly are trying to eliminate a government panel aimed at controlling Medicare spending seven months after they supported the health-care overhaul that created it.
Study: Arthritis drug co-developed by Lilly shows promise
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
Moody’s downgrades long-term ratings for Eli Lilly
Moody’s Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent expirations the drugmaker faces in coming years.
Lilly makes $300M deal for Philadelphia drug company
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
Appeals court rejects Lilly over Gemzar patent
Without an appeal, generic drugs are now poised to wipe away most of Lilly’s $750 million in annual U.S. revenue from Gemzar.
Indiana’s life sciences industry sees trouble ahead
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
Lilly diabetes setbacks may spur shopping for Amylin
Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc.
Analysts: Lilly setbacks might spur shopping spree
CEO John Lechleiter claims Eli Lilly and Co. isn’t interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
UPDATE: Lilly, others see stock slide after drug rejection
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.